BioMarin Pharma (BMRN) Misses Q2 EPS by 5c, Revenue Beats
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.53 -1.23%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $430 million versus the consensus estimate of $418.61 million.
GUIDANCE:
BioMarin Pharma sees 2020 revenue of $1.85-1.95 billion, versus the consensus of $1.9 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- BWS Financial Downgrades Inter Parfums (IPAR) to Sell
- Is Treasury selloff a major issue for stock market bulls?
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
